Engineering Antibody Agonists to Transform GPCR Targeting With Durable Biologics

• Stabilising GPCRs in active conformations to enable the generation of functional antibody agonists, a key hurdle in expanding biologic modalities for these targets
• Recognising the limitations of current GPCR antibodies which are predominantly antagonists or binders, and investing in technologies that support agonist development
• Leveraging the advantages of antibody agonists such as improved pharmacokinetics, longer half-life, and scalable manufacturing to create more durable and patient friendly therapies

Speakers:

Christel Menet

Chief Scientific Officer

Confo Therapeutics